Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Pediatric Brain Tumor
100%
Indoximod
100%
Radioimmunotherapy
100%
Overall Survival
67%
Brain Tumor
67%
Immune Response
45%
Tumor
45%
Diffuse Intrinsic Pontine Glioma
45%
Progression-free Survival
45%
Indoleamine 2,3-dioxygenase 1 (IDO1)
45%
Frontline Therapy
45%
Historical Control
45%
Immunological Therapy
45%
Pediatric Patients
32%
Patient Outcomes
22%
High Risk
22%
Refractory Patients
22%
Dying Tumor Cells
22%
Recurrent Medulloblastoma
22%
Comparator Study
22%
Treating children
22%
Prognostic Risk Stratification
22%
Conventional Radiation Therapy
22%
Solid Tumors
22%
Successful Outcome
22%
Temozolomide
22%
Apoptotic Cells
22%
Antigen Presentation
22%
Phase 1 Study
22%
Clinical Trials
22%
Low Toxicity
22%
Recurrent Brain Tumors
22%
Median Overall Survival
22%
Overall Time
22%
Pediatric
22%
Chemotherapy
22%
Recurring
22%
Genomic Features
22%
Conformal Radiotherapy
22%
Real Possibility
22%
Oral Inhibitors
22%
Newly Diagnosed
22%
Stratified Design
22%
Epigenomic Features
22%
Mechanistic Prediction
22%
Chemoimmunotherapy
22%
Recurrent GBM
22%
Cell-intrinsic
22%
Partial Fields
22%
Temozolomide Chemotherapy
22%
Hypothesis-driven
22%
Recurrent Ependymoma
22%
Natural Mechanism
22%
Single-arm Trial
22%
Historical Comparator
22%
Immunotherapy Approaches
22%
Immune Biomarkers
22%
Proof of Concept Study
22%
Immunogenic Antigen
22%
Effective Treatment
22%
Prolonged Survival
10%
Conventional Chemotherapy
10%
Inducing Mechanism
10%
Medicine and Dentistry
Pediatric Brain Tumor
100%
Immunotherapy
100%
Indoximod
100%
Overall Survival
90%
Intracranial Tumor
90%
Chemotherapy
54%
Pontine Glioma
45%
Temozolomide
45%
Progression Free Survival
45%
Immune Response
45%
Indoleamine 2,3 Dioxygenase
45%
Pediatrics Patient
32%
Neoplasm
22%
Antigen Presentation
22%
Pediatrics
22%
Arm
22%
Conformal Radiotherapy
22%
Ependymoma
22%
Clinical Trial
22%
Risk Stratification
22%
Solid Malignant Neoplasm
22%
Medulloblastoma
22%
Biological Marker
22%
Low Drug Dose
22%
Tumor Cell
22%
Chemoimmunotherapy
22%
Tumor
22%
Genetics
22%
Antigen
22%
Oral
22%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Intracranial Tumor
100%
Indoximod
89%
Overall Survival
80%
Chemotherapy Regimens
49%
Neoplasm
40%
Indoleamine 2,3 Dioxygenase
40%
Progression Free Survival
40%
Pontine Glioma
40%
Temozolomide
40%
Antigen
40%
Medulloblastoma
20%
Ependymoma
20%
Clinical Trial
20%
Solid Malignant Neoplasm
20%
Biological Marker
20%